Background
==========

Cholangiocarcinoma (CCA), tumor that arises from the epithelial cells of the bile duct, is a relatively rare cancer worldwide; however, its incidence is extremely high in Asia \[[@b1-medscimonit-21-3555]\]. Over the past three decades, the incidence of CCA appears to be increasing, and accounts for approximately 3% of all gastrointestinal carcinomas in Western countries \[[@b2-medscimonit-21-3555]\]. The percentage of patients who survive 5 years after diagnosis has not increased during this time period, remaining at 10% \[[@b3-medscimonit-21-3555]\]. CCA is notoriously difficult to diagnose owing to its nonspecific symptoms, the low sensitivity and specificity of most diagnostic modalities, and the lack of absolute diagnostic criteria. Therefore, timely diagnosis of CCA is sometimes a challenging task for clinicians.

MRI and CT with endoscopic ultrasound and PET provide useful diagnostic information in certain patients. However, tumor biomarkers provide significant help in the diagnosis and are increasingly attractive because of their noninvasive features and relative inexpensiveness. To date, the most studied and the most used tumor markers in clinical practice are carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) \[[@b4-medscimonit-21-3555]\]. Data suggests that the estimated sensitivity of CA 19-9 in predicting CCA in the context of primary sclerosing cholangitis is 38--89%, and a specificity is 50--98% \[[@b5-medscimonit-21-3555]\]. CA19-9 level can be normal in patients with localized diseases, and high CA19-9 levels can also occur in benign bile duct diseases, including cholangitis, calculus of bile duct, and nonmalignant jaundice \[[@b6-medscimonit-21-3555],[@b7-medscimonit-21-3555]\]. Therefore, there is insufficient evidence to confirm the diagnostic accuracy of CA19-9 in CCA.

To address this issue, we conducted a meta-analysis of all eligible studies to evaluate the role of CA19-9 in CCA diagnostic accuracy, and to find if CA19-9 could be a potential marker for detecting CCA, anticipating providing an evidence base for medicine.

Material and Methods
====================

Search strategy and inclusion criteria
--------------------------------------

Comprehensive databases have been used to identify the relevant studies published up to February, 2015. Databases include PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure (CNKI), and WANFANG databases. The following search terms were employed: "cholangiocarcinoma", "cholangiocellular", "gastrointestinal carcinoma"; "carbohydrate antigen 19-9", CA19-9; "blood", "serum", "circulating"; "diagnosis"; and "sensitivity and specificity" were used individually and in various pairwise combinations. All eligible studies were retrieved, and their bibliographies were checked for other relevant publications.

All eligible studies satisfying the following criteria were firstly included in our analysis: (1) CA19-9 was assessed in CCA diagnostic studies; (2) Patients were referred to confirmed CCA; (3) sensitivity (SEN) and specificity (SPE) of CA19-9 were reported to provide sufficient information to construct two×two contingency tables, or sufficiently detailed data were presented to derive these numbers. Exclusion criteria were as follows: (1) incomplete data to construct 2×2 contingency tables; (2) duplicate studies; and (3) reviews, letters and comments.

Data extraction and Quality assessment
--------------------------------------

Two reviewers (Liang and Zhong) reviewed and extracted the data from each eligible study independently. The following data were collected for each eligible study: Author's name, publication year, country, number of cases and controls, controls source, test method, sensitivity and specificity data, cut-off value. We assessed the methodological quality of the eligible studies for risk of bias and applicability using Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria. Any disagreement was resolved by consensus.

Statistical analyses
--------------------

Data were analyzed using STATA 12.0 software (Stata Corporation, College Station, TX) and Meta-Disc 1.4 software (XI Cochrane Colloquium, Barcelona, Spain). We extracted the numbers of all subjects with true positive (TP), true negative (TN), false positive (FP), and false negative (FN) from each included study, and the pooled SEN, SPE, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver operating characteristic curve (SROC) were analyzed using the bivariate meta-analysis model \[[@b8-medscimonit-21-3555]\]. An examination of the potential sources of heterogeneity is indispensable for any meta-analysis before pooling the data from the included studies into summary assessments. We used a Spearman correlation analysis to quantify the heterogeneity due to the threshold effect among the included studies. Moreover, the Cochran-*Q* test and the inconsistency index (*I^2^*) test were used to assess the non-threshold effect. When the result of the *Q*-test and *I^2^* statistics suggested heterogeneity (*P*≤0.05 and *I^2^*\>50%), a random-effects model (DerSimonian-Laird method) was used; otherwise, a fixed-effects model (Mantel-Haenszel method) was adopted. The Deeks funnel plots was applied to assess the potential publication bias among studies \[[@b9-medscimonit-21-3555]\], and *P*\<0.05 was considered to be representative of a significant statistical publication bias.

Results
=======

Literature search
-----------------

Flow chart for study selection was shown in [Figure 1](#f1-medscimonit-21-3555){ref-type="fig"}. In this study, we found 31 studies eligible for meta-analysis and the clinical characteristics were shown in [Table 1](#t1-medscimonit-21-3555){ref-type="table"} \[[@b10-medscimonit-21-3555]--[@b40-medscimonit-21-3555]\]. The 31 eligible studies included 1,264 patients of confirmed CCA and 2,039 controls. Of 31 studies, 19 studies were conducted in Asian countries \[[@b10-medscimonit-21-3555],[@b11-medscimonit-21-3555],[@b14-medscimonit-21-3555]--[@b22-medscimonit-21-3555],[@b24-medscimonit-21-3555]--[@b26-medscimonit-21-3555],[@b31-medscimonit-21-3555]--[@b33-medscimonit-21-3555],[@b40-medscimonit-21-3555]\], 7 studies in American countries \[[@b23-medscimonit-21-3555],[@b30-medscimonit-21-3555],[@b29-medscimonit-21-3555],[@b34-medscimonit-21-3555]--[@b36-medscimonit-21-3555],[@b39-medscimonit-21-3555]\], and 5 studies in European counties \[[@b12-medscimonit-21-3555],[@b13-medscimonit-21-3555],[@b27-medscimonit-21-3555],[@b37-medscimonit-21-3555],[@b38-medscimonit-21-3555]\]. The characteristics of the control groups varied among the 31 articles. Eight studies used PSC patients as a control group \[[@b23-medscimonit-21-3555],[@b29-medscimonit-21-3555],[@b30-medscimonit-21-3555] [@b34-medscimonit-21-3555],[@b36-medscimonit-21-3555]--[@b39-medscimonit-21-3555]\], and the other studies used a mix of healthy volunteers and patients with other diseases \[[@b10-medscimonit-21-3555]--[@b22-medscimonit-21-3555],[@b24-medscimonit-21-3555]--[@b28-medscimonit-21-3555],[@b31-medscimonit-21-3555]--[@b33-medscimonit-21-3555],[@b35-medscimonit-21-3555],[@b40-medscimonit-21-3555]\]. Among the 31 studies, 20 studies were small-size sample (\<100), and 11 studies were large-size sample (≥100). All studies were published from 1991 to 2015, and the sample sizes ranged from 22 to 320 subjects.

Quality assessment of the included studies
------------------------------------------

The risk of bias and applicability of the studies were evaluated based on QUADAS-2 summarized in [Figures 2](#f2-medscimonit-21-3555){ref-type="fig"} and [3](#f3-medscimonit-21-3555){ref-type="fig"}. A considerable proportion of studies (14/31, 45.2%) were considered to be at high risk of bias in the patient selection due to the case-control study design or inexplicit report. The index test domain in 13 studies (41.9%) was labeled as high risk of bias because the diagnostic threshold was not pre-specified. Concerning the flow and timing domain, four studies (12.9%) were considered at high risk of bias because the authors did not disclose whether all of the participants received the same reference standard.

Quantitative data synthesis
---------------------------

[Figure 4](#f4-medscimonit-21-3555){ref-type="fig"} showed the forest plot of diagnostic SEN and SPE of CA19-9 in all 31 included studies. The overall diagnostic SEN and SPE of CA19-9 were 0.72 (95% CI: 0.70--0.75) and 0.84 (95% CI: 0.82--0.85), respectively. SEN of individual studies ranged widely from 33% to 100%, while SPE of individual studies ranged from 31% to 100%. In addition, the pooled PLR, NLR, and DOR were 4.93 (95% CI, 3.67--6.64), 0.35 (95%CI, 0.30--0.41), and 15.10 (95% CI, 10.70--21.32), respectively. The SROC cure presents a global summary of test performance, and shows the tradeoff between SEN and SPE. In this meta-analysis, the area under the SROC curve was 0.8298, indicating a moderate and perfect level of overall accuracy, as shown in [Figure 5](#f5-medscimonit-21-3555){ref-type="fig"}.

Heterogeneity assessment and subgroup analysis
----------------------------------------------

All five performances showed high *I^2^* values: SEN, 58.2%; SPE, 87.8%; PLR, 84.6%; NLR, 58.9%; and DOR, 61.8% (all *P*\<0.01). This suggests substantial heterogeneity among the included studies. When heterogeneity of these 31 studies was tested, the Spearman correlation coefficient was 0.216 (*P*=0.236), which showed there must be factors other than threshold effect that results in the significant heterogeneity. Therefore, we performed subgroup analysis to investigate the possible sources of this heterogeneity according to geographical location, control group types, and sample size.

Subgroup analysis according to control group type showed that the type of control group (PSC group or Mixed group) had no noticeable effect on pooled SEN (0.73 \[95% CI: 0.70--0.76\] *vs.* 0.72 \[95% CI: 0.70--0.75\]), SPE (0.83 \[95% CI: 0.81--0.85\] *vs.* 0.83 \[95% CI: 0.81--0.85\]), PLR (4.69 \[95% CI: 3.25--6.79\] *vs.* 4.74 \[95% CI: 3.33--6.76\]), NLR (0.34 \[95% CI: 0.29--0.40\] vs. 0.35 \[95% CI: 0.30--0.41\]), DOR (14.21 \[95% CI: 9.64--20.95\] *vs.* 14.30 \[95% CI: 9.90--20.66\]), and AUC (0.8259 *vs.* 0.8271), as shown in [Table 2](#t2-medscimonit-21-3555){ref-type="table"}. Subgroups analysis according to geographical location clearly showed a high degree of variability in SEN estimates, whereas SPE in all subgroups were similar. The SEN in European subgroup is lower (0.62, 95% CI: 0.54--0.69) than Asian subgroup (0.74, 95% CI: 0.71--0.77) and American group (0.71, 95% CI: 0.62--0.79). In addition, we conducted subgroup analyses stratified by the sample size. For sample size \<100, the pooled SEN, SPE, PLR, NLR, DOR, and AUC were 0.69 (95% CI: 0.65--0.73), 0.79 (95% CI: 0.76--0.82), 4.33 (95% CI: 2.88--6.53), 0.40 (95% CI: 0.33--0.49), 12.34 (95% CI: 7.48--20.33), and 0.8207, respectively. The sample ≥100 improved the diagnostic power, with an increase in SEN of 0.75 (95% CI: 0.71--0.78), SPE of 0.84 (95% CI: 0.82--0.86), and DOR of 18.10 (95% CI: 11.00--29.78).

Publication bias
----------------

We tested potential publication bias using Deeks funnel plots. The funnel plots did not reveal any evidence of obvious asymmetry, which can be seen in [Figure 6](#f6-medscimonit-21-3555){ref-type="fig"}. The Deeks test also showed a statistically non-significant value (*P*=0.380), indicating that there was no potential publication bias.

Discussion
==========

CCA is regularly diagnosed at advanced stages due to the lack of early symptoms or reliable tumor biomarkers. Despite significant advances in molecular biology and diagnostic techniques, it remains one of the most frustrating diseases for gastroenterologists and surgeons. Reliable marker for diagnosis of CCA is crucial for treatment and prognosis. CA19-9, a member of the Lewis antigen family, has been studied intensively. Many studies evaluated the diagnostic role of CA 19-9 levels in patients with CCA, but the results from those studies were inconsistent. To derive a more precise estimate of the diagnostic significance of serum CA 19-9 in patients with CCA, we performed a meta-analysis of published studies. To the best of our knowledge, the present study is the first meta-analysis on the diagnostic role of serum CA 19-9 in patients with CCA, and the findings can provide valuable information for clinicians.

Thirty-one studies with a total of 3,303 subjects were finally included into the meta-analysis. Our data yields moderate diagnostic performances of CA19-9, in which the overall pooled sensitivity was 0.72 (0.70--0.75) and specificity was 0.84 (0.82--0.85). Moreover, the DOR is a single indicator of test accuracy that combines the sensitivity and specificity data into a single number. A DOR of 1.0 indicates inability to discriminate CCA patients from controls without it \[[@b41-medscimonit-21-3555]\]. In the present meta-analysis, we find that the DOR values for CA19-9 was 15.10 (95% CI, 10.70--21.32), indicating that CA19-9 could be helpful in the diagnosis of CCA. SROC is usually used to summarize overall test performance, and AUC is calculated to evaluate accuracy of the selected marker \[[@b42-medscimonit-21-3555]\].The AUROC value of 0.8300 indicates that CA19-9 could be a useful biomarker for CCA diagnosis. Overall, although the sensitivity is not as high as expected, CA19-9 has a good specificity in the diagnosis of CCA. Of note, 10% of individuals lack the Lewis antigen and do not produce CA 19-9, and occasionally tumor cells lose the ability to express a tumor marker \[[@b43-medscimonit-21-3555]\].

Most diagnostic evaluation show considerable heterogeneity between the included studies due to different factors. Therefore, we performed subgroup analyses according to geographical location, control type, and sample size for further description of the results. Our data suggested that CA199 had a relatively lower sensitivity of 62% in European group than in Asian group (74%) and American groups (71%), while the specificity was similar for three groups. This might be explained by different living backgrounds and different genetic factors between the three races. Another important reason may be that there is different range of cut-off values for CA199 levels and different assay methods in the included studies. Moreover, the small-size group (\<100) achieved low sensitivity and specificity than large-size group (≥100). Thus, well-designed studies with a large sample size that examine multiple ethnicities are required. In addition, some epidemiological data suggested that many studies involving different controls tend to show different sensitivity and specificity, and differ with those recruiting patients with clinically suspected disease, consecutively and prospectively in a representative clinical setting \[[@b44-medscimonit-21-3555]\]. Therefore, the distinct type of negative control may also be a main source of heterogeneity. PSC is one of the strongest risk factors for CCA with a lifetime risk of 5--15%, and annual incidence of CCA in PSC is 0.5--1% \[[@b45-medscimonit-21-3555],[@b46-medscimonit-21-3555]\]. We found that PSC control group displayed similar diagnostic performance with mixed control group; however, the conclusion was still consistent in the overall comparisons. This possible explanation could be the limited number of PSC patients included and different grade PSC-associated CCA studied. In addition, the subgroup analyses results showed that the above-mentioned factors do not significantly affect heterogeneity, suggesting that the influencing factors are complex. Therefore, more multi-center samples and empirical validations are still needed for a consensus on robust and accurate conclusion.

There are some limitations that need to be taken into account when interpreting the results of this study. First, the number of studies included in our meta-analysis, particularly the subgroup analysis according to control type, was limited, potentially limiting the comprehensive evaluation of diagnostic performance of CA19-9 in CCA and influencing the statistical power of results. Second, our analysis was not adjusted for confounding variables such as age, gender, life style, etc, due to incomplete information. Third, the relatively high heterogeneity presented in the 31 included studies is also the limitation of this study. Finally, only the published studies were collected and evaluated, and the unpublished studies with negative results were not included.

Conclusions
===========

The present meta-analysis suggested that serum CA19-9 is a reliable biomarker with a moderate sensitivity and high specificity for detecting CCA. Besides, our subgroup analysis showed diagnostic performance of CA19-9 was no significant difference in different control types, but showed low sensitivity in European patients and small size group. Large-scale studies should be carried out to further validate the clinical application of CA19-9 as an effective tumor marker of CCA.
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###### 

The characteristics of 31 eligible studies.

  Author                    Year   Country    Case/controls   Control type                                         Test method   Cut-off values   SEN/SPE
  ------------------------- ------ ---------- --------------- ---------------------------------------------------- ------------- ---------------- ---------------
  Li Y                      2015   China      30/30           HCC patients                                         CLIA          125.07 U/mL      76.67%/80.00
  Wang S                    2015   China      15/15           Normal controls                                      NA            28.915 ng/mL     66.7%/100%
  Lumachi F                 2014   Italy      24/25           Benign liver disease                                 CLIA          37 U/mL          74.1%/84.8%
  Voigtländer T             2014   Germany    49/48           PSC, BDS                                             NA            130 U/mL         53%/82%
  Kraiklang R               2014   Thailand   40/26           HCC, chronic biliary-liver disease                   NA            100 U/mL         44.4%/100%
  Ma H                      2012   China      54/42           Healthy control                                      CLIA          27 U/mL          81.48%/31.35%
  Leelawat K                2011   Thailand   50/50           Benign biliary tract disease                         CLIA          100 U/mL         72%/86%
  Jiang H                   2011   China      68/115          BDS                                                  CLIA          35 kU/L          73.53%/86.79%
  Leelawat K                2010   Thailand   59/128          Benign biliary tract disease                         CLIA          100 U/mL         68%/87%
  Li Y                      2009   China      115/205         Benign disease, blood donors                         EIA           37 U/mL          68.4%/75.0%
  Qin L                     2009   China      35/50           Benign biliary tract disease                         CLIA          39 U/mL          80%/860%
  Liu L                     2008   China      56/86           Benign hepatobiliary diseases, normal controls       EIA           NA               85.7%/100%
  Chen J                    2008   China      148/98          Benign polyp                                         CLIA          37 U/mL          82.43%/78.0%
  Charatcharoenwitthaya P   2008   USA        23/207          PSC                                                  CLIA          20 U/mL          78%/67%
  Uenishi T                 2007   Japan      71/90           Nonmalignant liver disease                           CLIA          39 U/mL          62.0%/92.2%
  Sun H                     2007   China      35/31           Benign biliary tract disease                         RIA           30 U/mL          80.00%/61.29%
  Leelawat K                2006   Thailand   33/51           Benign biliary tract disease, volunteer              CLIA          100 U/mL         60.6%/80.49%
  John AR                   2006   UK         68/38           Benign liver tumors, benign bile bile duct disease   CLIA          35 kU/L          67.5%/86.8%
  Qin X                     2005   China      51/42           Benign bile disease                                                37 kU/L          86%/86%
  Levy C                    2005   USA        14/194          PSC                                                  NA            129 U/mL         78.6%/98.5%
  Furmanczyk PS             2005   USA        4/18            PSC                                                  RIA           186 IU/mL        100%/94%
  Tangkijvanich P           2004   Thailand   45/10           Benign biliary disease                               EIA           100 U/mL         64.4%/100%
  Qin X                     2004   China      35/92           Benign biliary disease                               RIA           37 kU/L          77.14%/84.78%
  Wang Z                    2003   China      34/21           Benign polyp                                         RIA           37 U/mL          80.15%/92%
  Siqueira E                2002   USA        12/43           PSC                                                  RIA           180 U/mL         75.0%/97.3%
  Patel AH                  2000   USA        36/41           Nonmalignant liver disease                           RIA           100 U/mL         53%/76%
  Chalasani N               2000   USA        13/41           PSC                                                  NA            100 U/mL         75%/80%
  Björnsson E               1999   Sweden     9/63            PSC                                                  NA            200 ng/mL        38%/81%
  Ramage JK                 1995   England    15/59           PSC                                                  RIA           200 U/mL         60.0%/86.3%
  Nichols JC                1993   USA        9/28            PSC                                                  RIA           100 U/mL         89%/86%
  Pungpak S                 1991   Thailand   14/52           Normal control                                       RIA           43.1 U/mL        64.3%/98.1%

PSC -- primary sclerosing cholangitis; BDS -- bile duct stone; HCC -- hepatocellular carcinoma; CLIA -- chemiluminescent immunoassay; EIA -- sandwichenzyme-linked immunosorbent assay, RIA -- radioimmunoassay; SEN -- sensitivity; SPE -- specificity.

###### 

Summary of subgroup analysis of the included studies by different study characteristics.

  Variables               Number of studies   SEN (95%CI)         SPE (95%CI)         PLR (95%CI)          NLR (95%CI)         DOR (95%CI)            AUC
  ----------------------- ------------------- ------------------- ------------------- -------------------- ------------------- ---------------------- --------
  Overall                 31                  0.72 (0.70--0.75)   0.84 (0.82--0.85)   5.00 (3.68--6.78)    0.35 (0.30--0.41)   15.29 (10.72--21.80)   0.8300
  Control type                                                                                                                                        
   PSC                    8                   0.73 (0.70--0.76)   0.83 (0.81--0.85)   4.69 (3.25--6.79)    0.34 (0.29--0.40)   14.21 (9.64--20.95)    0.8259
   Mixed                  21                  0.72 (0.70--0.75)   0.83 (0.81--0.85)   4.74 (3.33--6.76)    0.35 (0.30--0.41)   14.30 (9.90--20.66)    0.8271
  Geographical location                                                                                                                               
   Asian                  19                  0.74 (0.71--0.77)   0.83 (0.81--0.85)   4.95 (3.28--7.46)    0.33 (0.28--0.39)   15.86 (10.34--24.32)   0.8346
   American               7                   0.71 (0.62--0.79)   0.84 (0.81--0.87)   8.47 (3.31--21.69)   0.31 (0.20--0.49)   32.74 (10.81--99.15)   0.8703
   European               5                   0.62 (0.54--0.69)   0.83 (0.78--0.88)   3.47 (2.43--4.94)    0.50 (0.36--0.69)   7.28 (3.95--13.44)     0.8947
  Sample size                                                                                                                                         
   ≥100                   11                  0.75 (0.71--0.78)   0.84 (0.82--0.86)   5.43 (3.65--8.06)    0.31 (0.26--0.37)   18.10 (11.00--29.78)   0.8189
   \<100                  20                  0.69 (0.65--0.73)   0.79 (0.76--0.82)   4.33 (2.88--6.53)    0.40 (0.33--0.49)   12.34 (7.48--20.33)    0.8207

SEN -- sensitivity; SPE -- specificity; PLR -- positive likelihood ratio; NLR -- negative likelihood ratio; DOR -- diagnostic odds ratio; AUC -- area under curve; CI-- confidence interval; PSC -- primary sclerosing cholangitis.
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